Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TERN

Terns Pharmaceuticals Inc

Dec 11 • 04:00PM ET

6.70

Dollar change -0.22
Percentage change -3.18	%

Healthcare • Biotechnology • USA • NASD

Peers: MDGL VKTX AKRO MNOV LGND GLMD BCRX XBIT ACAD AMRN

| Held by: VTI IWM VXF IWN IBB VTWO DFAC OZEM DFAS IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.18	Insider Own	26.82%	Shs Outstand	84.92M	Perf Week	-5.37%
Market Cap	569.09M	Forward P/E	-	EPS next Y	-1.33	Insider Trans	1.44%	Shs Float	62.16M	Perf Month	-10.19%
Income	-88.07M	PEG	-	EPS next Q	-0.30	Inst Own	71.51%	Short Float	8.66%	Perf Quarter	-29.55%
Sales	0.00M	P/S	-	EPS this Y	5.73%	Inst Trans	15.29%	Short Ratio	3.11	Perf Half Y	-9.34%
Book/sh	4.29	P/B	1.56	EPS next Y	-11.48%	ROA	-27.10%	Short Interest	5.39M	Perf Year	3.88%
Cash/sh	4.39	P/C	1.53	EPS next 5Y	-	ROE	-28.28%	52W Range	4.32 - 11.40	Perf YTD	3.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.40%	ROI	-24.10%	52W High	-41.23%	Beta	-0.38
Dividend TTM	-	Quick Ratio	32.99	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	55.09%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	32.99	EPS Y/Y TTM	6.80%	Oper. Margin	-	RSI (14)	51.63	Volatility	6.85% 7.75%
Employees	66	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.50	Target Price	19.21
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	32.24%	Payout	-	Rel Volume	0.58	Prev Close	6.92
Sales Surprise	-	EPS Surprise	12.64%	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	1.73M	Price	6.70
SMA20	6.99%	SMA50	-3.19%	SMA200	-5.36%	Trades		Volume	1,011,042	Change	-3.18%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-24	Initiated	Oppenheimer	Outperform	$82
Jun-22-23	Initiated	Mizuho	Buy	$16
Jun-07-23	Initiated	Jefferies	Buy	$18
May-31-23	Initiated	ROTH MKM	Buy	$23
May-08-23	Initiated	BMO Capital Markets	Outperform	$18
Feb-14-23	Initiated	JMP Securities	Mkt Outperform	$17
Feb-07-23	Initiated	UBS	Buy	$19
Sep-12-22	Initiated	H.C. Wainwright	Neutral	$6
Sep-14-21	Resumed	Goldman	Buy	$21
Mar-02-21	Initiated	JP Morgan	Overweight	$32
Mar-02-21	Initiated	Goldman	Buy	$29
Mar-02-21	Initiated	Cowen	Outperform

Show Previous Ratings

Dec-03-24 07:00AM	Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia (GlobeNewswire)
Dec-02-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-18-24 04:05PM	Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors (GlobeNewswire) -7.62%
Nov-12-24 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire) -5.44%
Nov-06-24 04:05PM	Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Oct-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -5.08%
Sep-24-24 03:22AM	Insiders Snap Up These 2 Strong Buy Stocks (TipRanks)
Sep-18-24 10:07AM	This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments (Motley Fool) +6.02%
Sep-17-24 01:30AM	OrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals Inc (GuruFocus.com)
Sep-15-24 07:21AM	Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. (Motley Fool)
06:09AM	Should You Invest in This Under-the-Radar Weight Loss Stock? (Motley Fool)
Sep-14-24 10:12AM	1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More (Motley Fool)
Sep-12-24 07:00PM	Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -10.96% -5.84%
Sep-10-24 10:50PM	Terns Announces Pricing of Upsized $150.15 Million Public Offering (GlobeNewswire) +23.14%
04:52AM	Terns Pharmaceuticals reports positive data from Phase I trial of obesity treatment (Clinical Trials Arena)
04:01PM	Loading…
Sep-09-24 04:01PM	Terns Announces Proposed Public Offering (GlobeNewswire) +16.77%
09:58AM	Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill (Barrons.com)
09:24AM	Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month (Benzinga)
08:06AM	Early study data puts Terns among obesity drug contenders (BioPharma Dive)
07:05AM	Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity (GlobeNewswire)
Aug-28-24 09:55AM	Wall Street Analysts Think Terns Pharmaceuticals (TERN) Could Surge 78.74%: Read This Before Placing a Bet (Zacks)
Aug-05-24 09:56PM	TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Aug-02-24 01:54PM	3 Biotech Stocks That Could Have Investors Grinning Soon (InvestorPlace)
Aug-01-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-29-24 04:05PM	Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition (GlobeNewswire) -7.55% -7.92%
Jul-26-24 06:40PM	Burger King Parent Company and More Stocks See Action From Activist Investors (Barrons.com)
Jul-20-24 09:30AM	Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? (Motley Fool)
Jun-21-24 06:30PM	Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation (GlobeNewswire)
Jun-19-24 01:27PM	Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue? (Zacks)
09:55AM	Loading…
Jun-04-24 09:55AM	Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade (Zacks)
Jun-03-24 04:10PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
May-30-24 08:05AM	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-17-24 04:05PM	Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day (GlobeNewswire) +5.93%
May-13-24 01:53PM	TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024 (InvestorPlace) +5.94%
09:32AM	Terns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss Projections (GuruFocus.com)
08:05AM	Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-08-24 04:05PM	Terns Pharmaceuticals Announces Leadership Changes (GlobeNewswire) +5.03%
May-07-24 04:05PM	Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024 (GlobeNewswire)
May-03-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.43%
Apr-29-24 04:05PM	Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation (GlobeNewswire)
Apr-10-24 04:05PM	Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer (GlobeNewswire) -5.23%
Mar-14-24 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates (GlobeNewswire) -5.23% +7.30%
Mar-11-24 04:05PM	Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia (GlobeNewswire) -8.38%
Mar-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Feb-27-24 04:05PM	Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences (GlobeNewswire) +5.69% -6.26%
Feb-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.13% +9.81%
08:05AM	Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer (GlobeNewswire)
Feb-02-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-04-24 04:05PM	Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.52%
Jan-03-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-29-23 04:05PM	Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit (GlobeNewswire) +6.97%
Nov-27-23 04:05PM	Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer (GlobeNewswire) +5.96%
Nov-14-23 12:16PM	Terns Pharmaceuticals Inc (TERN) Reports Q3 2023 Financials and Corporate Progress (GuruFocus.com) +5.34%
08:05AM	Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Nov-13-23 08:05AM	Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR- Agonist TERN-501 in NASH at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 08:05AM	Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire) -21.89%
Nov-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-02-23 04:05PM	Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity (GlobeNewswire) -8.00%
Oct-19-23 04:05PM	Terns Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.61%
Oct-16-23 08:05AM	Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia (GlobeNewswire)
Oct-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-06-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-05-23 04:05PM	Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-08-23 04:15PM	Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire) -13.73%
04:05PM	Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR- Agonist TERN-501 in NASH (GlobeNewswire)
Aug-03-23 06:00PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -6.80%
05:05PM	Terns Pharmaceuticals Announces Leadership Transition (GlobeNewswire)
Jul-28-23 07:01PM	Deep Track Capital, LP Enters Position in Terns Pharmaceuticals Inc (GuruFocus.com)
Jul-18-23 04:05PM	Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia (GlobeNewswire) +5.17%
Jul-05-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jun-26-23 04:05PM	Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADAs 83rd Annual Scientific Session and Upcoming Events (GlobeNewswire) -12.16% -23.52%
Jun-06-23 04:30PM	Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-02-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +5.17%
May-28-23 09:45AM	Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth (Simply Wall St.)
May-25-23 05:05PM	Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting (GlobeNewswire)
May-24-23 04:05PM	Terns Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-22-23 04:05PM	Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Associations 83rd Annual Scientific Sessions (GlobeNewswire) +11.79% +6.12%
May-15-23 08:05AM	Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire) -6.24%
May-09-23 04:05PM	Terns Pharmaceuticals to Participate in the JMP Securities 2023 Life Sciences Conference (GlobeNewswire)
May-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.61%
Apr-25-23 12:00PM	Terns Pharmaceuticals, Inc. (TERN) Is Up 15.12% in One Week: What You Should Know (Zacks) -5.29%
Mar-30-23 02:28PM	Why Shares of Terns Pharmaceuticals Soared This Week (Motley Fool)
Mar-27-23 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates (GlobeNewswire) +5.83% +13.24%
08:05AM	Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology (GlobeNewswire)
Mar-08-23 05:26AM	Investing in Terns Pharmaceuticals (NASDAQ:TERN) a year ago would have delivered you a 211% gain (Simply Wall St.)
Mar-02-23 04:05PM	Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences (GlobeNewswire)
Feb-26-23 10:51AM	TipRanks Perfect 10 List: 3 Top-Rated Stocks That Tick All the Right Boxes (TipRanks)
Feb-08-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Terns Pharmaceuticals, Inc. (TERN) is a Great Choice (Zacks)
Feb-02-23 04:05PM	Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference (GlobeNewswire) +5.26%
Jan-12-23 04:05PM	Terns Pharmaceuticals to Present at B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire) +8.83%
Jan-05-23 04:05PM	Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.67%
Dec-23-22 04:05PM	Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -7.20% +8.24%
Dec-20-22 07:40PM	Terns Announces Pricing of $75 Million Public Offering (GlobeNewswire) -5.59%
08:05AM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-19-22 04:31PM	Terns Announces Proposed Public Offering (GlobeNewswire) +30.28%
Dec-01-22 04:05PM	Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit (GlobeNewswire) -10.30% -8.03%
Nov-16-22 09:31AM	We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate (Simply Wall St.)
Nov-09-22 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) -8.10% -16.23%
Nov-04-22 08:05AM	Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022 (GlobeNewswire)

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burroughs Amy L.	Chief Executive Officer	Dec 05 '24	Buy	7.15	15,450	110,468	19,099	Dec 09 06:04 PM
Lu Hongbo	Director	Sep 12 '24	Buy	10.50	476,190	4,999,995	476,190	Sep 17 07:48 PM
Vignola Mark J.	Chief Financial Officer	Sep 10 '24	Option Exercise	5.36	10,000	53,600	101,940	Sep 12 06:10 PM
Vignola Mark J.	Chief Financial Officer	Sep 10 '24	Sale	11.00	10,000	110,000	91,940	Sep 12 06:10 PM
Quigley Jill M.	Director	Sep 09 '24	Option Exercise	1.82	17,235	31,368	32,235	Sep 11 06:00 PM
Quigley Jill M.	Director	Sep 09 '24	Sale	10.00	17,235	172,350	15,000	Sep 11 06:00 PM
SEOKHO BRYAN YOON	Officer	Sep 10 '24	Proposed Sale	9.12	10,000	91,200		Sep 10 04:21 PM
MARK J VIGNOLA	Officer	Sep 10 '24	Proposed Sale	9.12	10,000	91,200		Sep 10 04:21 PM
JILL QUIGLEY	Officer	Sep 09 '24	Proposed Sale	7.81	8,857	69,173		Sep 09 04:30 PM
Quigley Jill M.	Director	Aug 02 '24	Sale	7.50	8,857	66,432	15,000	Aug 05 08:11 PM
Quigley Jill M.	Director	Aug 01 '24	Sale	7.68	6,143	47,148	23,857	Aug 05 08:11 PM
GORDON CARL L	Director	Jul 15 '24	Sale	10.00	50,976	509,760	756,258	Jul 17 08:53 PM
GORDON CARL L	Director	Jul 16 '24	Sale	10.00	5,188	51,880	755,635	Jul 17 08:53 PM
ORBIMED ADVISORS LLC	Director	Jul 15 '24	Sale	10.00	50,976	509,760	756,258	Jul 17 08:48 PM
ORBIMED ADVISORS LLC	Director	Jul 16 '24	Sale	10.00	5,188	51,880	755,635	Jul 17 08:48 PM
Quigley Jill M.	Director	Jul 15 '24	Option Exercise	1.82	14,365	26,144	44,365	Jul 17 07:56 PM
Quigley Jill M.	Director	Jul 16 '24	Option Exercise	1.82	400	728	30,400	Jul 17 07:56 PM
Quigley Jill M.	Director	Jul 15 '24	Sale	10.00	14,365	143,660	30,000	Jul 17 07:56 PM
Quigley Jill M.	Director	Jul 16 '24	Sale	10.00	400	4,000	30,000	Jul 17 07:56 PM
Vivo Opportunity, LLC	10% Owner	Apr 01 '24	Sale	6.99	181,117	1,266,008	275,772	Apr 03 08:47 PM
Vivo Opportunity, LLC	10% Owner	Apr 03 '24	Sale	6.20	138,066	856,009	268,573	Apr 03 08:47 PM
Vivo Opportunity, LLC	10% Owner	Apr 02 '24	Sale	6.65	101,480	674,842	272,722	Apr 03 08:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TERN

Terns Pharmaceuticals Inc

Upgrade your FINVIZ experience